Ubs Group Ag Y M Abs Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 44,586 shares of YMAB stock, worth $356,688. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,586

Previous 19,004 134.61%

Holding current value

$356,688

Previous $229,000 155.46%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$9.95 - $15.39 $254,540 - $393,706	25,582 Added 134.61%	44,586 $585,000
Q2 2024 Aug 13, 2024	SELL	$11.6 - $17.25 $215,098 - $319,866	-18,543 Reduced 49.39%	19,004 $229,000
Q1 2024 May 13, 2024	BUY	$6.57 - $18.69 $5,275 - $15,008	803 Added 2.19%	37,547 $610,000
Q4 2023 Feb 09, 2024	BUY	$4.88 - $7.42 $83,989 - $127,705	17,211 Added 88.11%	36,744 $250,000
Q3 2023 Nov 09, 2023	SELL	$4.86 - $7.23 $7,455 - $11,090	-1,534 Reduced 7.28%	19,533 $106,000
Q2 2023 Aug 11, 2023	SELL	$5.68 - $10.34 $313,513 - $570,726	-55,196 Reduced 72.38%	21,067 $143,000
Q1 2023 May 12, 2023	BUY	$2.83 - $5.11 $215,824 - $389,703	76,263 New	76,263 $382,000
Q3 2022 Nov 10, 2022	SELL	$13.96 - $19.67 $181,131 - $255,218	-12,975 Reduced 50.75%	12,594 $182,000
Q2 2022 Aug 10, 2022	SELL	$8.22 - $15.13 $892,757 - $1.64 Million	-108,608 Reduced 80.94%	25,569 $387,000
Q1 2022 May 16, 2022	BUY	$6.55 - $17.42 $456,718 - $1.21 Million	69,728 Added 108.19%	134,177 $1.59 Million
Q4 2021 Feb 14, 2022	BUY	$15.51 - $29.31 $603,183 - $1.14 Million	38,890 Added 152.16%	64,449 $1.05 Million
Q3 2021 Nov 15, 2021	BUY	$27.47 - $37.31 $664,966 - $903,163	24,207 Added 1790.46%	25,559 $729,000
Q2 2021 Aug 13, 2021	BUY	$25.45 - $37.64 $31,736 - $46,937	1,247 Added 1187.62%	1,352 $45,000
Q1 2021 May 12, 2021	BUY	$29.16 - $51.96 $1,458 - $2,598	50 Added 90.91%	105 $3,000
Q4 2020 Feb 11, 2021	BUY	$37.86 - $54.26 $1,476 - $2,116	39 Added 243.75%	55 $3,000
Q3 2020 Nov 12, 2020	SELL	$35.13 - $43.62 $7,131 - $8,854	-203 Reduced 92.69%	16 $1,000
Q2 2020 Jul 31, 2020	SELL	$23.66 - $49.53 $116,454 - $243,786	-4,922 Reduced 95.74%	219 $9,000
Q1 2020 May 01, 2020	BUY	$14.39 - $35.8 $71,100 - $176,887	4,941 Added 2470.5%	5,141 $134,000
Q4 2019 Feb 14, 2020	SELL	$23.81 - $33.78 $371,031 - $526,393	-15,583 Reduced 98.73%	200 $6,000
Q3 2019 Nov 14, 2019	BUY	$21.57 - $31.37 $289,534 - $421,079	13,423 Added 568.77%	15,783 $411,000
Q2 2019 Aug 14, 2019	BUY	$19.51 - $28.31 $17,305 - $25,110	887 Added 60.22%	2,360 $54,000
Q1 2019 May 14, 2019	SELL	$18.21 - $26.21 $40,080 - $57,688	-2,201 Reduced 59.91%	1,473 $39,000
Q4 2018 Feb 14, 2019	BUY	$15.41 - $28.92 $56,616 - $106,252	3,674 New	3,674 $75,000

Others Institutions Holding YMAB

# of Institutions

106

Shares Held

24.5M

Call Options Held

40.3K

Put Options Held

400

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $350M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account